Traders bought shares of Medtronic Inc. (NYSE:MDT) on weakness during trading on Thursday. $73.38 million flowed into the stock on the tick-up and $49.25 million flowed out of the stock on the tick-down, for a money net flow of $24.13 million into the stock. Of all companies tracked, Medtronic had the 15th highest net in-flow for the day. Medtronic traded down ($0.05) for the day and closed at $87.08

A number of research analysts have recently weighed in on the company. Jefferies Group restated a “buy” rating on shares of Medtronic in a research report on Wednesday, June 1st. BTIG Research lowered Medtronic from a “buy” rating to a “neutral” rating and set a $82.00 price objective for the company. in a research report on Wednesday, June 1st. Bank of America Corp. restated a “buy” rating on shares of Medtronic in a research report on Sunday, May 22nd. Credit Suisse Group AG restated a “buy” rating and set a $85.00 price objective on shares of Medtronic in a research report on Tuesday, May 31st. Finally, Needham & Company LLC restated a “buy” rating and set a $93.00 price objective (up previously from $90.00) on shares of Medtronic in a research report on Tuesday, May 31st. Six equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $88.50.

The stock has a market cap of $121.40 billion and a price-to-earnings ratio of 35.10. The stock has a 50-day moving average of $87.68 and a 200-day moving average of $80.98.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, May 31st. The medical technology company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.01. During the same period last year, the company earned $1.16 EPS. The firm earned $7.57 billion during the quarter, compared to analysts’ expectations of $7.49 billion. The business’s quarterly revenue was up 3.6% on a year-over-year basis. On average, equities research analysts anticipate that Medtronic Inc. will post $4.66 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 27th. Stockholders of record on Friday, July 8th were issued a $0.43 dividend. This is a boost from Medtronic’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Wednesday, July 6th. This represents a $1.72 annualized dividend and a dividend yield of 1.98%.

In other news, VP Richard Kuntz sold 49,905 shares of the company’s stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $82.60, for a total value of $4,122,153.00. Following the transaction, the vice president now directly owns 127,647 shares in the company, valued at approximately $10,543,642.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Shirley A. Jackson sold 2,104 shares of the company’s stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $88.64, for a total transaction of $186,498.56. Following the completion of the transaction, the director now owns 34,503 shares in the company, valued at $3,058,345.92. The disclosure for this sale can be found here.

Several institutional investors recently modified their holdings of the company. Condor Capital Management raised its position in shares of Medtronic by 1.1% in the fourth quarter. Condor Capital Management now owns 17,351 shares of the medical technology company’s stock valued at $1,335,000 after buying an additional 195 shares in the last quarter. Farr Miller & Washington LLC DC raised its position in shares of Medtronic by 0.4% in the fourth quarter. Farr Miller & Washington LLC DC now owns 314,555 shares of the medical technology company’s stock valued at $24,196,000 after buying an additional 1,216 shares in the last quarter. Smith Salley & Associates raised its position in shares of Medtronic by 1.6% in the fourth quarter. Smith Salley & Associates now owns 83,879 shares of the medical technology company’s stock valued at $6,452,000 after buying an additional 1,286 shares in the last quarter. Tradition Capital Management LLC raised its position in shares of Medtronic by 2.3% in the fourth quarter. Tradition Capital Management LLC now owns 85,935 shares of the medical technology company’s stock valued at $6,610,000 after buying an additional 1,950 shares in the last quarter. Finally, Advantus Capital Management Inc raised its position in shares of Medtronic by 2.1% in the fourth quarter. Advantus Capital Management Inc now owns 135,663 shares of the medical technology company’s stock valued at $10,435,000 after buying an additional 2,730 shares in the last quarter.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.